Bristol Myers Squibb®

Have you or a loved one been diagnosed with relapsed or refractory multiple myeloma (RRMM)?

The QUINTESSENTIAL Study is now enrolling adults with relapsed* or refractory† multiple myeloma, known as RRMM, who have received at least three prior lines of therapy.

*Relapsed cancer occurs when the disease goes into remission and comes back.
†Refractory cancer occurs when the disease stops responding to treatment and continues to progress.

Ask your doctor for more information about this clinical study.

Study number: CA088-1000
Version: V1.0

QUINTESSENTIAL

Research for multiple myeloma (MM)

As you may know, multiple myeloma (MM) is a blood cancer that begins in the bone marrow, where a type of white blood cell called plasma cells are formed. Some plasma cells become cancerous. These cancerous plasma cells accumulate and crowd out healthy blood cells, leading to bone fractures, kidney failure, low blood counts, and increased risk of infections.

Despite available treatments, most patients experience relapsed or refractory MM, known as RRMM, and there is a great need for options that may achieve better outcomes for those who have already tried multiple different therapies. Right now, research is underway to evaluate an investigational therapy that could address RRMM in a different way, and you or your loved one may be able to take part.

Patients who take part in clinical studies may help the development of potential options for future patients.

To learn more about RRMM clinical studies, visit: BMS.SparkCures.com

Evaluating a potential new therapy option

This study is evaluating an investigational immunotherapy called **chimeric antigen receptor (CAR) T cell therapy**.

- A **CAR** is a special receptor (a structure that receives a message to act a certain way in the body) created by scientists. CARs are made to connect with certain proteins on a cell.
- **T cells** are a kind of white blood cell that attacks foreign invaders in the body.

In CAR T cell therapy, T cells are removed from a person's blood, and then, in a laboratory, the T cells are introduced to a CAR that teaches them to target and attack the cause of disease symptoms. Next, these T cells, now called CAR T cells, are multiplied in the laboratory and returned to the same person's bloodstream through an infusion at a later time.

CAR T cell therapy is being evaluated for use in many cancers, immune-mediated diseases, and autoimmune conditions. It has been an option for several types of cancers and is FDA approved as a therapy for leukemia, lymphoma, and multiple myeloma.[1]

Researchers believe that, when used to address RRMM, CAR T cell therapy may help the body destroy certain disease-causing cells, potentially leading to disease improvement or remission.

1. cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1

Study timeline



*Lymphodepleting; lymphodepleting and leukapheresis are described on Page 6.

To learn more about RRMM clinical studies, visit: BMS.SparkCures.com

About the QUINTESSENTIAL Study

The QUINTESSENTIAL Study is evaluating the safety and effectiveness of an investigational CAR T cell therapy in adults with RRMM.

About 150 individuals will be enrolled in this study. Participation will last up to five years after your last infusion and consists of three main periods.

About the QUINTESSENTIAL Study

Study period details

- **Pre–study treatment period:** At screening, certain tests and procedures may be done to make sure you are eligible to participate in the study. To partake in the study, you will need to stop receiving your current treatment(s). The study doctor will go over this process with you in detail.
  - In preparation for the investigational therapy, you will complete a procedure called **leukapheresis**. You will be connected to a machine that circulates your blood to collect T cells, which will then be genetically modified at a BMS laboratory before they are returned to your bloodstream at a later time. This procedure may take a few hours.
- **Study treatment period:** Following a single infusion of the investigational therapy, you will be monitored for at least one week. Some patients may be hospitalized during this week. After this, you will attend clinic visits and undergo tests and assessments such as vital sign measurements, physical and routine neurological exams, blood and urine sample collections, bone imaging, a bone marrow biopsy, and questionnaires.
  - Before receiving the investigational therapy, you will undergo a treatment known as **lymphodepleting (LD) chemotherapy**. This is administered to reduce certain white blood cells in the body so that they do not attack the CAR T cells that are introduced during the investigational therapy infusion.

Remember that even if you qualify for a clinical study, it is always your decision to participate.

To learn more about RRMM clinical studies, visit: BMS.SparkCures.com

- **Post–study treatment follow-up period:** After you have completed the full treatment period and are sent home, the study team will continue to check on your health through study visits. These visits will include tests and assessments such as physical and routine neurological exams, blood and urine sample collections, bone marrow biopsies, and questionnaires. You will attend one visit every three months for two years (eight total) and then every six months for up to three years (six total). You can also choose to be monitored for long-term safety for up to 15 years.

If eligible, you may receive:

- Study-related medical care
- Study-related laboratory work and procedures

If you're interested in joining the QUINTESSENTIAL Study, talk to your doctor. Together, you can decide if participating may be right for you.

How do I qualify for this study?

Eligible participants must:

- Be at least 18 years of age
- Have a diagnosis of RRMM
- Have received at least three prior lines of MM therapy

There are additional eligibility criteria, which your study doctor can explain to you.

While enrolled in this study, you will not be responsible for study-related costs, such as visits, laboratory tests, and procedures. You will also be eligible for reimbursement for some costs, like time, travel, or transportation, depending on your location. Talk to the study team to learn more.

To learn more about RRMM clinical studies, visit: BMS.SparkCures.com

Questions to discuss with your health care provider

These questions may be used as starting points when discussing the QUINTESSENTIAL Study with your doctor.

- Has the investigational therapy been tested before?
- What are the potential benefits of participating?
- What are the potential risks of participating?
- Will you still be involved in my care?
- Will the study affect my current treatment plan?
- Why might this study be a good fit for me?
- What are my other options if I don't join this study?

Bristol Myers Squibb is committed to improving inclusion of diverse patients in our clinical studies so that participation is more reflective of the real-world population.

Notes

To learn more about RRMM clinical studies,
visit: BMS.SparkCures.com

Notes

Bristol Myers Squibb®

Notes

Study number: CA088-1000

To learn more about RRMM clinical studies, visit: **BMS.SparkCures.com**

Thank you

for considering a clinical study

CA088-1000_Recruitment Brochure_V1_03Oct2023_US_ENG

QUINTESSENTIAL